Cantor Fitzgerald Initiates Coverage on Compugen

Having written about Compugen in earlier posts ("Investing Then and Now, Compugen" and "Compugen, Evolving Case for Business Schools"), I was gratified to learn that Cantor Fitzgerald last week initiated coverage on Compugen. Cantor Fitzgerald's analyst stated:

"We think Compugen's predictive platform portfolio can streamline identification/validation of relevant biomarkers/therapeutic targets — a paradigm shift in discovery/development programs that can mitigate risk, condense timelines, and exponentially increase pharma's output of both diagnostics and therapeutics...In our view, Compugen is the emerging leader in next-generation discovery a design and development methodology — using a market-disruptive approach integrating millions of genome experiments into a series of discovery engines."